This HCC CONNECT e-learning programme helps to provide an understanding of the management of patients with advanced or unresectable HCC and who could benefit from VEGFR-TKI monotherapy in first-line setting

The international faculty for this HCC CONNECT virtual Experts Knowledge address “Appropriate selection of patients for first-line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs”. The faculty explore the profile of patients with advanced or unresectable HCC  who could benefit from VEGFR-TKI monotherapy in first-line setting, explore real-world evidence, discuss the safety profile of the monotherapies, look into the future, with the potential promising combination therapies in the treatment of HCC and also provides an update on key HCC data presented recently at ASCO GI 2022.

This accredited e-learning will provide you with an overview of selection of patients for 1st line monotherapy in HCC

  • The patient-profile who could benefit from VEGFR-TKI monotherapy 1st line in advanced or unresectable HCC
  • Real-world data with monotherapy and the implications for clinical practice
  • The safety profile of the monotherapies, be able to recognise the cause of toxicities and know the appropriate dosing strategies to manage side effects
  • A look into the future, the potential of combination therapies in the treatment of HCC

Meeting Video Chapters

00:00   Faculty and Disclaimer

00:15   Who Can Benefit from VEGFR-TKI Monotherapy Today? Prof Finn

18:38   What did we learn from the real-world data? What can we translate into clinical practice? Dr Bouattour

36:44   Treating patients with VEGFR-TKI monotherapy:
           What are the treatment related AEs and how to manage them? Prof Harding

56:06   Latest updates in HCC from ASCO GI 2022 (HIMALAYA study, KEYNOTE-394 trial, LAUNCH study). Dr Choo

1:18:42 A look to future treatments. Prof Finn

Dr Richard Finn is a professor of Medicine at the Geffen School of Medicine at UCLA in the Department of Medicine, Division of Hematology/Oncology. He was an undergraduate at UCLA where he was involved with early laboratory studies investigating the HER2 oncogene and the development of monoclonal antibodies to this target in breast cancer with Dr Dennis Slamon. He participated in the pre-clinical studies that defined the clinical candidate that eventually humanized and became the FDA approved agent trastuzumab (Herceptin). He went on to medical school at USC then returned to UCLA for his clinical training in Internal Medicine and then Hematology/ Oncology. He currently splits his time between patient care and directing the Translational Research Laboratory in the Division of Hematology/Oncology. His research interests are focused in the development of targeted therapeutics for solid tumors across histologies to support the larger efforts of the department. His personal interests lie in the development of these targeted agents in Hepato-biliary and breast cancers. He has two-half days dedicated to patient care, one of which is as a leader in the multi-disciplinary hepato-biliary cancer program at UCLA where he is involved with clinical studies aimed at bringing novel therapeutics into the treatment of patients with these malignancies.

Dr Mohamed Bouattour is a physician in the Department of Digestive Oncology and Consultant in the Department of Hepatology at Beaujon University Hospital and has held this these positions since November 2007. He is board certified in Gastroenterology-Hepatology and Medical Oncology. He has expertise in the field of liver tumours, hepatocellular carcinoma, and pre-clinical and clinical research for liver disease. Dr Bouattour works in close collaboration with a multidisciplinary team including, liver surgeons, radiologists, oncologists, hepatologists and pathologists, to improve the management of patients with liver cancers. Dr Bouattour has been involved in presenting several collaborative works in national and international scientific meetings. He has authored and co-authored scientific papers in the field of liver and cancer diseases. He is investigator and sub investigator for several phase 1, 2 and 3 clinical trials. Dr Bouattour is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology (ASCO). Relevant Publications Coriat R, Faivre SJ, Mir O, Dreyer C, Ropert S, Bouattour M, Desjardins R, Goldwasser F, Raymond E. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. Int J Nanomedicine 2016; 21; 11: 6207-6216. Bouattour M, Soubrane O, de Gramont A, Faivre S. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. Trials 2016; 25; 17(1): 563. Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20):2245-63. Bouattour M, Rousseau B, Wassermann J, Payancé A, Huillard O. Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors? J Clin Oncol 2015; 33(22): 2484-5. Dreyer C, Sablin MP, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S. Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol 2015; 7(6): 910-5. Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M, Boige V. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Invest New Drugs 2014; 32(5): 1028-35. Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist 2014; (4): 394-402. Ozenne V, Bouattour M, Goutté N, Vullierme MP, Ripault MP, Castelnau C, Valla DC, Degos F, Farges O. Prospective evaluation of the management of hepatocellular carcinoma in the elderly. Dig Liver Dis 2011; 43(12):1001-5.

Dr Mohamed Bouattour has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, BMS, Eisai, MSD, Roche and Sirtex Medical. 

Dr James Harding is a board-certified medical oncologist at Memorial Sloan Kettering Cancer Center in New York, USA. He specializes in caring for people with liver cancer, gallbladder cancer, and bile duct cancer. His primary goal is to provide the best possible treatment and individualized care for people with these diseases.  In his research, he is trying to find new, effective therapies for gastrointestinal cancer, particularly primary liver and bile duct tumors. For example, he is working on ways to use a patient’s own immune system to fight cancer (immunotherapy). In addition, Dr Harding is investigating strategies to block specific cellular pathways that cancer uses to grow. He has helped develop and lead numerous national and international clinical trials of these new cancer therapies for patients with liver, bile duct cancers, and other solid tumors.  Dr Harding’s research and training has been supported by the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the National Institutes of Health, the American Association for Cancer Research, and the Howard Hughes Medical Institute.  His work has been published in the New England Journal of Medicine, Nature, Nature Medicine, the Journal of Clinical Oncology, Cancer Discovery, Clinical Cancer Research, and Cancer. Relevant publications Harding  JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D'Angelica MI, Berger MF, Hyman DM, Jarnagin WR, Klimstra DS, Janjigian YY, Solit DB, Schultz N, Abou-Alfa  GK.  Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research 2018. OCT 29   Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein E, Intlekofer AM.  Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition.  Cancer Discov 2018 Oct 24.   Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK.  A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.  Cancer Chemother Pharmacol 2018 Sep;82(3):429-440   Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK.  Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.  J Natl Compr Canc Netw 2018 Jan;16(1):50-58.   Harding JJ, El Dika I, Abou-Alfa GK.  Immunotherapy in hepatocellular carcinoma: Primed to make a difference?  Cancer 2016 Feb 1;122(3):367-77.

Prof. James Harding has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bristol Myers, Eisai and Eli Lilly

BMedSci, BMBS(Nottm), MRCP(UK), FAMS Dr Choo Su Pin is a medical oncologist at Curie Oncology who specializes in gastrointestinal cancers. She graduated from the University of Nottingham Medical School, UK before returning to Singapore. She has fellowships from the Royal College of Physicians, UK and the Academy Of Medicine, Singapore and was trained in medical oncology at the National Cancer Centre Singapore (NCCS) where she was Chief of Gastrointestinal Oncology. She also did a research fellowship at the University of California San Francisco. Her research areas of interest include pancreatico-hepatobiliary cancers and early phase trials. Relevant publications: Wong DJ, Lee J, Choo SP et al. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. Immunotherapy 2019 Feb;11(3):167-175 Koh YX, Tan HL, Lye WK, Kam JH, Chiow AKH, Tan SS, Choo SP, Chung AYF, Goh BKP. Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. World J Hepatol 2018 Jun 27;10(6):433-447 Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP et al. Phase II studies with refametinib or refametinib plus sorafenib in patient with RAS-mutated Hepatocellular Carcinoma. Clin Cancer Res 2018 Oct 1;24(19):4650-4661 Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, Choo SP et al; Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018 Jul 1;36(19):1913-1921. Teo JY, Allen JC, Ng DCE, Abdul Latiff JB, Choo SP et al. Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinoma. Surgery 2018 May;163(5):1008-1013 Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol 2018 Jan 20;36(3):276-282 Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, Choo SP et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov 2017 Oct;7(10):1116-1135 El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017 Jun 24;389(10088):2492-2502 Zhai W, Lim TK, Zhang T, Phang ST, Tiang Z, Guan P, Ng MH, Lim JQ, Yao F, Li Z, Ng PY, Yan J, Goh BK, Chung AY, Choo SP et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat Commun 2017 Feb 27;8:4565 Chay WY, Tham CK, Toh HC, Lim HY, Tan CK, Lim C, Wang WW, Choo SP. Coriolus versicolor (Yunzhi) Use as Therapy in Advanced Hepatocellular Carcinoma Patients with Poor Liver Function or Who Are Unfit for Standard Therapy. J Altern Complement Med 2017 Aug;23(8):648-652. Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartono S, Thng CH, Huynh H, Lim KT, Toh HC, Goh BC, Choo SP. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann Oncol 2016 Dec;27(12):2210-2215 Choo SP, Tan WL, Goh BK, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer 2016 Nov 15;122(22):3430-3446. Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 2013 Dec;45(12):1474-8

Dr Su Pin Choo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, BMS, Eisai, MSD and Sirtex. 

Programme summary
Take the e-learning now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Eisai
This course has been accredited by EACCME® for 1 ECMEC®.
I agree that this educational programme:

Was valuable to me

Brought to you by

HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer, AstraZeneca and from Eisai Europe Limited.

Meet the experts

Other programmes of interest

podcast Podcast
Prostate cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 1 of a 3-part video podcast series

Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
  • download Downloadable
  • clock 30 MIN
  • calendar Nov 2023

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
tweetorial Tweetorial
Tweetorial video: Navigating ER+ metastatic breast cancer

Explore a patient case from testing, diagnosis and treatment

Dr Paolo Tarantino
Endorsed by
  • clock 9 MIN
  • calendar Nov 2023

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology
interactive-patient-case Interactive patient case



of 2

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

An interactive patient case video series from breast cancer specialists

Prof. Valentina Guarneri
Endorsed by
  • clock 15 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology
conference-update Conference update
GI highlights from ESMO 2023

An expert panel discussion hosted by COR2ED and eChinaHealth

  • clock 50 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from BeiGene Europe and SystImmune.
conference-update Conference update
RCC Update from ESMO 2023

How will the latest data impact clinical practice?

Prof. Laurence Albiges
  • download Downloadable
  • clock 4 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Eisai Europe Limited.
conference-update Conference update
Lung cancer highlights from ESMO 2023

An expert panel discussion hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Oct 2023

This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.